修订版国际分期系统2危险分层对接受自体造血干细胞移植的多发性骨髓瘤患者结局的影响
该回顾性分析纳入1291例接受 upfront 自体造血干细胞移植的新诊断多发性骨髓瘤患者,评估R2-ISS的预后效用。中位随访42.2个月,R2-ISS I、II、III、IV期的中位PFS分别为73.0、65.2、44.0、24.8个月(p<0.001),中位OS分别为130.8、128.5、94.2、61.4个月(p<0.001)。多因素分析中,以R2-ISS I期为参照,III期和IV期与显著更差的PFS相关,仅IV期与显著更差的OS相关。
要点
- R2-ISS I、II、III、IV期分布为123例(10%)、471例(36%)、566例(44%)、131例(10%)。
- 中位PFS随R2-ISS分期递增而缩短:I期73.0个月、II期65.2个月、III期44.0个月、IV期24.8个月(p<0.001)。
- 多因素分析以I期为参照,III期PFS的HR为1.55(95%CI 1.05-2.29;p=0.028),IV期PFS的HR为2.04(95%CI 1.24-3.36;p=0.005)。
核心结论
- R2-ISS是接受upfront自体造血干细胞移植的新诊断多发性骨髓瘤患者的可靠预后工具。
研究设计与样本
- 回顾性分析,纳入1291例接受upfront自体造血干细胞移植的新诊断多发性骨髓瘤患者,中位年龄62岁(范围29-83)。
主要发现
- R2-ISS I、II、III、IV期分布分别为123例(10%)、471例(36%)、566例(44%)、131例(10%)。
- 中位随访42.2个月(范围0.3-181.0),中位PFS分别为73.0、65.2、44.0、24.8个月(p<0.001),中位OS分别为130.8、128.5、94.2、61.4个月(p<0.001)。
- PFS多因素分析以R2-ISS I期为参照,III期HR 1.55(95%CI 1.05-2.29;p=0.028),IV期HR 2.04(95%CI 1.24-3.36;p=0.005),均与显著更差的PFS相关。
- OS多因素分析以R2-ISS I期为参照,仅IV期与显著更差的OS相关(HR 2.43,95%CI 1.18-5.01;p=0.017)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The second revision of the International Staging System (R2-ISS) is a simple tool to risk-stratify newly diagnosed multiple myeloma (NDMM) patients. Here, we completed a retrospective analysis to evaluate the utility of R2-ISS in NDMM patients who underwent up-front autologous haematopoietic stem cell transplantation (auto-HCT). A total of 1291 patients were included, with a median age of 62 years (range 29-83). The distribution of R2-ISS stages was: 123 (10%) stage I, 471 (36%) stage II, 566 (44%) stage III and 131 (10%) stage IV. With a median follow-up of 42.2 months (range 0.3-181.0), the median PFS was 73.0, 65.2, 44.0 and 24.8 months, (p < 0.001) and the median OS was 130.8, 128.5, 94.2 and 61.4 months (p < 0.001) for patients with R2-ISS stages I, II, III and IV respectively. On multivariable analysis (MVA) for PFS, using R2-ISS stage I as reference, R2-ISS stages III (hazard ratio [95% confidence interval], 1.55 [1.05-2.29]; p = 0.028) and IV (2.04 [1.24-3.36]; p = 0.005) were associated with significantly inferior PFS. In the MVA of OS, using R2-ISS stage I as reference, only R2-ISS stage IV was associated with significantly inferior OS (2.43 [1.18-5.01]; p = 0.017). Overall, we found that R2-ISS is a reliable prognostic tool for NDMM patients undergoing up-front auto-HCT.
引用
- Alzahrani K, Pasvolsky O, Wang Z, et al. Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation. Br J Haematol. 2024. PMID: 38448009. doi:10.1111/bjh.19384
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。